Acadia, NPS, Ironwood sell more than $300m in stock
This article was originally published in Scrip
Executive Summary
Large stock offerings by three publicly traded drug developers are testing the investor love affair with industry during a year in which the Nasdaq Biotechnology Index has skyrocketed 73% from 1094.71 on 3 January to 1893.44 as of 21 May.